(San Diego) May 3 rd , 2022 – Cellics Therapeutics, Inc., a biotech startup company using the innovative Cellular Nanoparticle (CNP) Technology for the treatment and prevention of
infectious and inflammatory diseases, announced today that the U.S. Food and Drug Administration (FDA) has allowed the Investigational New Drug (IND) application for its lead drug product CTI-005, Human Red Blood Cell Nanosponges, for patients hospitalized with methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-sensitive Staphylococcus aureus (MSSA) pneumonia. With the IND allowance, the company plans to start the clinical trial, which will be a multicenter, randomized, double-blind, placebo-controlled Phase 1b/2a trial investigating the safety and potential efficacy of CTI-005 in MRSA and MSSA pneumonia patients.

CTI-005 are nanoparticles made of human red blood cell membranes. Leveraging the natural receptors on the red blood cell membranes, CTI-005 can neutralize toxins secreted by MRSA or MSSA bacteria and thus enable the innate human immune system to kill the bacteria. This anti-virulence approach for the treatment of bacterial infection may overcome the drug resistance problem of traditional antibiotics and be especially effective against antibiotic-resistant bacteria such as MRSA as shown by the significant survival benefits in the preclinical pharmacology study of this IND.

Read more...